URGN Q4 2020 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

$7M91.8% margin

Operating Income

-$27M-342.1% margin

Net Income

-$31M-383.2% margin

EPS (Diluted)

$-1.38

QoQ Revenue Growth

+130.2%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$122M

Total Liabilities

$26M

Stockholders' Equity

$96M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	$7M	$0	—
Operating Income	-$27M	-$40M	+31.6%
Net Income	-$31M	-$39M	+21.7%